Outcomes of Influenza with Treatment in Patients with Diabetes: Subgroup Analysis of the Phase 3 CAPSTONE-2 Trial

被引：0

作者：

Ison, Michael G. ^{[1
]}

Castro, Rita de Cassia ^{[2
]}

Hurt, Aeron C. ^{[3
]}

Ko, Jinnie ^{[2
]}

Yau, Linda ^{[2
]}

Kuhlbusch, Klaus ^{[3
]}

Portsmouth, Simon ^{[4
]}

Hayden, Frederick G. ^{[5
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Genentech Inc, San Francisco, CA 94080 USA

[3] F Hoffmann Roche Ltd, Basel, Switzerland

[4] Shionogi Inc, Florham Pk, NJ USA

[5] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2021年 / 116卷

关键词：

influenza; diabetes; antiviral; baloxavir; oseltamivir;

D O I：

10.1016/j.metabol.2020.154624

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0157

引用

页码：63 / 63

页数：1

共 50 条

[1] BALOXAVIR MARBOXIL FOR THE TREATMENT OF INFLUENZA VIRUS INFECTION IN PATIENTS WITH CARDIOVASCULAR DISEASE: A SUBGROUP ANALYSIS OF CAPSTONE-2
Collins, Colleen
Han, Jian
Cagas, Steven E.
Stephens, John
Sun, Christy
Kuhlbusch, Klaus
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1632 - 1632
[2] Efficacy and Safety of Baloxavir Marboxil for the Treatment of Influenza Virus Infection in Patients with Chronic Lung Disease: A Subgroup Analysis of CAPSTONE-2
Cagas, S.
Gupta, S.
Han, J.
McIntosh, M.
Collins, C.
Sun, C.
Kuhlbusch, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[3] Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial
Ison, Michael G.
Portsmouth, Simon
Yoshida, Yuki
Shishido, Takao
Mitchener, Melissa
Tsuchiya, Kenji
Uehara, Takeki
Hayden, Frederick G.
LANCET INFECTIOUS DISEASES, 2020, 20 (10): : 1204 - 1214
[4] Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial
Portsmouth, Simon
Hayden, Frederick G.
Kawaguchi, Keiko
Ishibashi, Toru
Kinoshita, Masahiro
Shishido, Takao
Tsuchiya, Kenji
Uehara, Takeki
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (04) : 477 - 484
[5] Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Min, Kyung-Wan
Ku, Bon Jeong
Lee, Ji-Hyun
Kim, Min-Seon
Ahn, Kyu-Jeung
Lee, Moon-Kyu
Kokubo, Satoshi
Yoshida, Satoshi
Cho, Hyun-Ji
Cha, Bong-Soo
DIABETES & METABOLISM JOURNAL, 2017, 41 (02) : 135 - 145
[6] Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes
Onishi, Yukiko
Oura, Tomonori
Nishiyama, Hiroshi
Ohyama, Sumika
Takeuchi, Masakazu
Iwamoto, Noriyuki
ENDOCRINE JOURNAL, 2016, 63 (03) : 263 - 273
[7] Week 48 outcomes in aflibercept 8 mg-and 2 mg-treated patients by prior DME treatment status: a subgroup analysis of the phase 2/3 PHOTON trial
Mehta, Nitish
Mehta, Nitish
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[8] Outcomes of Antiviral Treatment for Influenza in Type 2 Diabetes
Lewing, Benjamin D.
Wallick, Christopher
To, Tu My
Masters III, Henry
Dayal, Parul
Korom, Stephan W.
Tam, Selina
AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (02): : E43 - E50
[9] Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
Xu, Jianming
Xu, Rui-Hua
Qin, Shukui
Pan, Hongming
Bai, Yuxian
Chi, Yihebali
Wang, Liwei
Bi, Feng
Cheng, Ying
Liu, Tianshu
Ma, Dong
Shen, Lin
Ba, Yi
Liang, Jun
Wang, Xin
Yau, Thomas C. C.
Ma, Brigette B.
Yeh, Kun-Huei
Lin, Jen-Kou
Kappeler, Christian
Shapiro, Jo Ann
Kalmus, Joachim
Li, Jin
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (08) : 1307 - 1316
[10] Subgroup Analysis of East Asian Patients in the Phase III REVEL Trial
Kang, Jin-Hyoung
Park, Keunchil
Kim, Joo-Hang
Cho, Eun Kyung
Shih, Jin-Yuan
Zimmermann, Annamaria H.
Lee, Pablo
Alexandris, Ekaterine
Puri, Tarun
Orlando, Mauro
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S323 - S323

← 1 2 3 4 5 →